CANADABIS CAPITAL INC (CANB.CA) Stock Fundamental Analysis

Canada • TSX Venture Exchange • TSX-V:CANB • CA13530Q1046

0.03 CAD
+0 (+20%)
Last: Feb 2, 2026, 07:00 PM
Fundamental Rating

2

CANB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. CANB has a medium profitability rating, but doesn't score so well on its financial health evaluation. CANB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year CANB has reported negative net income.
  • In the past year CANB has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: CANB reported negative net income in multiple years.
  • In the past 5 years CANB reported 4 times negative operating cash flow.
CANB.CA Yearly Net Income VS EBIT VS OCF VS FCFCANB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

1.2 Ratios

  • CANB has a Return On Assets (-5.26%) which is in line with its industry peers.
  • CANB has a Return On Equity (-16.69%) which is in line with its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.62%, CANB is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CANB is above the industry average of 8.73%.
  • The 3 year average ROIC (12.44%) for CANB is well above the current ROIC(1.62%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -5.26%
ROE -16.69%
ROIC 1.62%
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
CANB.CA Yearly ROA, ROE, ROICCANB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

  • CANB's Operating Margin of 1.90% is fine compared to the rest of the industry. CANB outperforms 66.67% of its industry peers.
  • CANB's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 45.50%, CANB is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CANB has grown nicely.
Industry RankSector Rank
OM 1.9%
PM (TTM) N/A
GM 45.5%
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
CANB.CA Yearly Profit, Operating, Gross MarginsCANB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CANB is creating value.
  • CANB has about the same amout of shares outstanding than it did 1 year ago.
  • CANB has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CANB has a worse debt to assets ratio.
CANB.CA Yearly Shares OutstandingCANB.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CANB.CA Yearly Total Debt VS Total AssetsCANB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • CANB has an Altman-Z score of 0.22. This is a bad value and indicates that CANB is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.22, CANB is in the better half of the industry, outperforming 60.61% of the companies in the same industry.
  • A Debt/Equity ratio of 1.00 is on the high side and indicates that CANB has dependencies on debt financing.
  • CANB has a worse Debt to Equity ratio (1.00) than 75.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z 0.22
ROIC/WACC0.24
WACC6.73%
CANB.CA Yearly LT Debt VS Equity VS FCFCANB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • CANB has a Current Ratio of 1.33. This is a normal value and indicates that CANB is financially healthy and should not expect problems in meeting its short term obligations.
  • CANB's Current ratio of 1.33 is on the low side compared to the rest of the industry. CANB is outperformed by 63.64% of its industry peers.
  • CANB has a Quick Ratio of 1.33. This is a bad value and indicates that CANB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CANB has a Quick ratio of 0.27. This is amonst the worse of the industry: CANB underperforms 87.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 0.27
CANB.CA Yearly Current Assets VS Current LiabilitesCANB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • CANB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -720.00%.
  • CANB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.84%.
  • The Revenue has been growing by 30.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-720%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-35.88%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CANB.CA Yearly Revenue VS EstimatesCANB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CANB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANB.CA Price Earnings VS Forward Price EarningsCANB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CANB is valued a bit cheaper than 69.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.66
CANB.CA Per share dataCANB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CANB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CANADABIS CAPITAL INC

TSX-V:CANB (2/2/2026, 7:00:00 PM)

0.03

+0 (+20%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-29
Earnings (Next)03-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners53.52%
Ins Owner ChangeN/A
Market Cap4.14M
Revenue(TTM)15.08M
Net Income(TTM)-1.29M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.27
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA 8.66
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.11
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.26%
ROE -16.69%
ROCE 2.15%
ROIC 1.62%
ROICexc 1.73%
ROICexgc 1.73%
OM 1.9%
PM (TTM) N/A
GM 45.5%
FCFM N/A
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
ROICexc(3y)15.4%
ROICexc(5y)N/A
ROICexgc(3y)15.4%
ROICexgc(5y)N/A
ROCE(3y)15.95%
ROCE(5y)N/A
ROICexgc growth 3Y-38.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-38.64%
ROICexc growth 5YN/A
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
F-Score1
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA 6.65
Cap/Depr 7.85%
Cap/Sales 0.46%
Interest Coverage 0.86
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 0.27
Altman-Z 0.22
F-Score1
WACC6.73%
ROIC/WACC0.24
Cap/Depr(3y)67.82%
Cap/Depr(5y)55.13%
Cap/Sales(3y)2.43%
Cap/Sales(5y)2.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-720%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-35.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.84%
EBIT growth 3Y-19.31%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-161.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-147.44%
OCF growth 3YN/A
OCF growth 5YN/A

CANADABIS CAPITAL INC / CANB.CA FAQ

Can you provide the ChartMill fundamental rating for CANADABIS CAPITAL INC?

ChartMill assigns a fundamental rating of 2 / 10 to CANB.CA.


What is the valuation status of CANADABIS CAPITAL INC (CANB.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to CANADABIS CAPITAL INC (CANB.CA). This can be considered as Overvalued.


How profitable is CANADABIS CAPITAL INC (CANB.CA) stock?

CANADABIS CAPITAL INC (CANB.CA) has a profitability rating of 4 / 10.


Can you provide the financial health for CANB stock?

The financial health rating of CANADABIS CAPITAL INC (CANB.CA) is 2 / 10.